Kreglinger Europe and Averix Bio have announced the execution of a distribution and supply agreement. Averix is a US-based manufacturer of CBD APIs for nutraceuticals, pharmaceuticals, food and cosmetics, and through this agreement, Kreglinger will be responsible for distributing these ingredients to manufacturers across Europe.
Wim Arnouts, Chief Executive Officer (CEO) at Kreglinger Europe, said, “Kreglinger is a trusted ingredient supplier to the pharmaceutical, food-supplement, cosmetic, food and beverage industries in the EU and UK. With demand for CBD products on the rise, we plan to meet the needs of our customers with the best ingredients available. We have been interested in the cannabinoid space for some time but had not found a supplier with the rigorous compliance standards that we felt necessary to enter the market. We found that high standard in Averix.
“Regulatory and safety concerns are always an issue for new products entering the market. To minimise risk, companies will choose ingredients that provide high compliance standards to meet quality and safety requirements. Averix Bio is a US FDA registered manufacturer of GMP Part 210 and ICH Q7 API products. These are the qualifications our customers are looking for.”
Mark Ward, Chief Revenue Officer (CRO) of Averix Bio said: “We are excited to have been chosen by Kreglinger to bring API CBD isolate into the European market. The growth opportunity for cannabinoid products is expanding everywhere and consumer appetite in Europe is very high. Kreglinger is a well-known distributor with long-standing success, outstanding reputation, and an established customer network throughout Europe. They supply industry leading companies that demand their suppliers provide the best ingredients available.”
